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Abstract
In the last two decades, a large increase in opioid overdose death rates has been recorded
in North America. This phenomenon, related to the misuse of prescription opioids,
has been dubbed an “opioids crisis”. Recent years have seen the entrance of novel
synthetic opioids (NSO) on the market, compounding the fatal intoxications issue. This
brings several challenges for forensic toxicology laboratories: an increased number of
cases, a large number of novel structurally similar compounds to include in screening
analytical methods, the low concentration of drugs in biological fluids, and the challenging
interpretation in the absence of sufficient literature. Three cases of fatal intoxication
highlighting those challenges are presented, complete with post-mortem concentrations
in cardiac blood, femoral blood and urine. Toxicological screening and quantitative
analyses were performed on the biological specimens. In the first and second cases,
furanylfentanyl, U-47700 and 4-anilino-N-phenethylpiperidine (4-ANPP) were detected
at similar concentrations in cardiac blood. In the third case, a total of seventeen different
NSO were detected. All intoxications showed a combination of NSO and other drugs.
These three cases appear to be the harbinger of an increased NSO prevalence in the
province of Que´bec, Canada.
1. Introduction
In recent years, North America has experienced a considerable growth in mortality
related to misuse of prescribed opioids [1, 2, 3, 4] that has been dubbed an “opioids
crisis”. However, the number of deaths resulting from commonly prescribed opioids has
been stable since 2012 in the United States and Canada [4, 5, 6]. The increase of fatal
opioids overdoses observed since then can be tied to the appearance of novel synthetic
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opioids (NSO) on the market, alone or in combination with other drugs, mainly heroin [4].
These new psychoactive substances (NPS) are derivatives of well-known prescribed opi-
oids, failed pharmaceuticals or medicinal products [7]. Amongst the reasons for NPS’
production is the will to generate substances that are not controlled by national or in-
ternational regulations, but still generate psychoactive effects for the user [7].
NSO are generally categorized as fentanyl analogs (e.g., acetylfentanyl, butyrylfen-
tanyl, furanylfentanyl) or as non-fentanyl compounds (e.g., U-47700, AH-7921, mitrag-
ynine) [3]. Even though some non-pharmaceutical fentanyls (e.g., alpha-methylfentanyl,
3-methylfentanyl) were seen on the market as early as 1979 [8, 9], the recent diversifica-
tion of NSO intertwined with the opioids epidemic has resulted in a major public health
concern in North America. In Canada, 2,978 deaths were related to opioids during 2016.
Of these, 55% were related to fentanyl and NSO specifically. One year later, in 2017, the
number of deaths had increased by 34% to 3,987, and NSO and fentanyl were involved
in 72% of cases [2]. The crisis shows no sign of slowing down in the United States either.
Between 2015 and 2016, the death rate from synthetic opioids and fentanyl (excluding
methadone) doubled, bringing the percentage of drug overdose deaths involving opioids
to 66% [4].
For forensic toxicology laboratories, NPS and NSO bring major challenges. NSO’s
structural similarity demands highly specific analytical methods, and their low biological
concentrations call for high sensitivity [10, 11, 12]. In addition, new NSO compounds
regularly appear on the market [10], requiring an adjustment in analytical methods and
rapid production of new certified reference materials (CRMs) [7].
Three cases of intoxication highlighting those challenges are presented therein. These
fatal overdoses occurred between January 2018 and February 2018 in the province of
Que´bec, Canada. Detailed results of quantitative analysis of various post-mortem ma-
trices and qualitative analysis of physical evidence collected at the scene are also included.
2. Methods
2.1. Sample collection and storage
A complete autopsy was performed on each victim. Peripheral blood from the femoral
vein, cardiac blood pooled from both ventricles, urine, gastric contents and vitreous hu-
mor were collected for toxicological analyses. Femoral blood and vitreous humor were
stored in a BD Vacutainer storage tube (part number 367001, Franklin Lakes, USA)
containing 100 mg of sodium fluoride and 20 mg of potassium oxalate as a preserva-
tive. Cardiac blood and urine were stored in 50 mL polypropylene tubes (Sarstedt, part
number 62.559.001, Newton, NC, USA). 500 mg of a mixture of sodium fluoride and
phosphate oxalate (5:1, wt:wt) was added to cardiac blood as preservative. All samples
were stored at 4 ◦C until completion of the toxicological analyses. Since very little is
known about the stability of NSO in biological matrices, occurrence of degradation is
not precluded and this should be kept in mind when interpreting concentrations.
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2.2. Toxicological analysis
Blood alcohol content was determined in biological matrices via gas chromatogra-
phy coupled to a flame ionization detector (GC-FID) (Agilent 6890 A and 6890 N)
method. Briefly, 100 μL of biological matrix is mixed with 1 mL of a tert-butanol so-
lution (5 mg/mL) and heated to equilibrium in a sealed vial; 1 mL of the headspace
is injected. Other common volatile substances (isopropanol, acetone, methanol and n-
propanol) were also screened for.
Femoral blood, cardiac blood and urine samples extracts were submitted to a high
throughput liquid chromatography coupled with tandemmass spectrometry (LC-MS/MS)
screening and quantification assay covering 144 xenobiotics [13] including the NSO bu-
tyrylfentanyl, furanylfentanyl and carfentanil. A 100 μL volume of biological matrix
was mixed with an internal standard solution comprising 36 deuterated compounds and
precipitated with 400 μL of a 7:3 (v:v) acetonitrile:acetone mixture. A 25 μL volume of
supernatant was diluted in 180 μL of 0.2% formic acid prior to the injection of a 5 μL
aliquot on an Agilent Zorbax Eclipse Plus C18 column (2.1mm × 100mm, 3.5 μm). This
method was carried out on an Agilent 1200 HPLC coupled to a Sciex 5500 QTrap oper-
ated in positive electrospray ionization mode with multiple reaction monitoring (MRM).
General unknown screening was carried out using a solid phase extraction preparation
(Oasis HLB cartridges, Waters, part number WAT094226, Mississauga, ON, Canada) fol-
lowed by a gas chromatography coupled with mass spectrometry and nitrogen-phosphorus
detectors (GC-MS/NPD) analysis (Agilent 7890/5975 MSD). National Institute of Stan-
dards and Technology (NIST), Cayman Chemical and local spectrum libraries were mined
for possible matches.
All quantitative methods were validated according to the Scientific Working Group
for Forensic Toxicology (SWGTOX) guidelines [14], and were accredited under ISO
17025:2005 and CAN-P 1578 standards.
2.3. Quantification of NSO
Confirmation and quantification of NSO were performed via LC-MS/MS by NMS
Labs (Willow Grove, PA, USA) [15], with an extended method heavily based on [16].
3. Results
3.1. Case 1
A 46-year-old woman, known alcoholic, was found dead in her unsanitary apartment.
Putrefactive changes were apparent on the body, such as a large green stain across her
abdomen.
The woman was 158 cm tall and weighed 55 kg. A complete autopsy and histolog-
ical examination of the heart, liver, kidneys and endometrium tissues were performed.
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Overall, no traumatic or pre-existing lesions could be considered as the cause of death.
Toxicological analysis was performed on urine as well as cardiac and femoral blood.
Results, shown in Table 1, highlight the consumption of methamphetamine, cocaine,
methadone at recreational levels and the NSO furanylfentanyl and U-47700. 4-ANPP, a
metabolite and precursor of fentanyl related NSO [17, 18], was also detected.
The cause of death was determined to be drug polyintoxication.
3.2. Case 2
A 30-year-old man was found in cardiorespiratory arrest in his father’s kitchen. Re-
suscitation attempts were unsuccessful. The victim had a history of drug and alcohol
addiction. He had been in jail a few weeks before the incident, and had reported be-
ing dependent to oxycodone since. The man had a record of active prescriptions for
pregabalin, methylphenidate and clonazepam. At the time of the incident, about 10
clonazepam tablets were reported missing.
The man was 172 cm tall and weighed 84 kg. Six broken ribs observed in autopsy were
attributed to the reanimation procedures. Furthermore, the coronary artery presented
moderate to severe atherosclerosis which was confirmed by histological examinations of
the tissue. No other traumatic lesions were found.
Toxicological analysis was performed on urine as well as cardiac and femoral blood.
Results (Table 1) reveal the presence of several prescription drugs and drugs of abuse,
including the NSO furanylfentanyl, 4-ANPP and U-47700. Δ9-tetrahydrocannabinol
(THC), clonazepam, pregabalin and methylphenidate were found at therapeutic/recrea-
tional levels, whereas diazepam, naproxen and nortriptyline were present in trace amounts.
A program for free access to naloxone in drugstores was in place at the time of the
events. Nevertheless, there is no toxicological evidence of naloxone administration in this
case.
The cause of death was declared to be a polyintoxication with the likely contribution
of coronary atherosclerosis.
Interestingly, deceased individuals in cases 1 and 2 were both found in the same city,
and had similar blood concentrations of furanylfentanyl and U-47700. This suggests the
two cases might be related (e.g., victims knew each other or had the same drug dealer),
but this possibility was not further investigated by law enforcement.
3.3. Case 3
A 29-year-old man was found dead with a syringe in his hand and empty bottles
of steroid nearby. Large putrefactive changes were apparent on the body. The victim
had a history of drug consumption, but had undergone a drug addiction rehabilitation
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Table 1: Analytical findings in each fatality
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program. The man was 172 cm tall and weighed 89 kg. No traumatic or pre-existing
lesions were noted during autopsy.
In the initial toxicological analysis, femoral and cardiac blood as well as urine were
analyzed using the high throughput LC-MS/MS screening and quantification method.
General unknown GC-MS screening was also performed on femoral blood and urine.
These analyses revealed alprazolam, quetiapine and gabapentin at therapeutic levels
(Table 1), as well as the presence of duloxetine. Three weeks later, evidence collected on
the scene was sent to the forensic laboratory by police investigators for chemical analysis.
The general unknown GC-MS assay of this white powder and syringe using the newly
updated Cayman Chemical GC-MS Library revealed the presence of several NSO, all
listed in Table 1.
These new results changed the outlook on the case, and prompted a retrospec-
tive analysis of femoral blood GC-MS chromatograms with the newly updated Cay-
man Chemical GC-MS library. This new data mining revealed the presence of para-
fluoro(iso)butyrylfentanyl, methoxyacetylfentanyl, and 4-ANPP. The two first were also
identified in urine, along with p-fluorofentanyl, U-47700, isobutyrylfentanyl, butyrylfen-
tanyl and valerylfentanyl. These biological matrices were therefore sent for confirmation
and quantitative analysis at NMS Labs. Complete results are reported in Table 1.
A later analysis with an LC-MS/MS NSO screening method under development re-
vealed several additional NSO both in the white powder and the biological matrices
(Table 1). Although butyrylfentanyl was initially identified in the white powder by the
high throughput LC-MS/MS assay, further investigation using an LCMS/MS method in
development revealed that isobutyrylfentanyl was actually present in the sample (Fig-
ure 1). Similarly, U-51754 identified by GC-MS was revealed to actually be U-48800.
Para-fluoro(iso)butyrylfentanyl, cyclopropylfentanyl/crotonylfentanyl, despropionyl pa-
ra-fluorofentanyl and N-methyl U-47931 E were identified as the main components of the
white powder, with a proportion exceeding 10% (w:w). All other NSO can be considered
to be present at trace levels in the powder, although it should be noted that a quanti-
tative evaluation was not possible for methoxyacetylfentanyl due to the lack of available
standard at the moment of analysis.
Cause of death was determined to be a polyintoxication.
4. Discussion
The arrival of NSO on the recreational market is an unprecedented phenomenon that
generates several challenges for forensic laboratories. Forensic toxicologists have to deal
with an increasing number of cases, often presenting several analytical and interpretation
challenges.
In the United States, the misuse and addiction to opioids has spread throughout the
country, although certain regions are much more impacted than others [19]. In Canada,
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(a) LC-MS/MS Chromatograms of the selected MRM transitions
(m/z 351.2 − > 188.0 and m/z 351.2 − > 105.0) for the butyrylfen-
tanyl reference standard and the white powder exhibit under the
high throughput LC-MS/MS screening.
(b) LC-MS/MS Chromatograms of the selected MRM transitions
for the butyrylfentanyl (m/z 351.2 − > 188.0 and m/z 351.2 − >
105.0) and isobutyrylfentanyl (m/z 351.2 − > 188.0 and m/z 351.2
− > 105.0) reference standards analyzed individually, and together
as part of an NSO mix under the targeted NSO LC-MS/MS anal-
ysis method currently in development.
Figure 1: LC-MS/MS chromatograms
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the opioids crisis unfurled west to east, beginning its route in British Columbia and
then the prairies (Alberta, Saskatchewan, Manitoba) [20]. The province of Ontario re-
ported in 2017 a sudden increase in opioid related deaths [20]. Until now, it seemed like
the province of Que´bec was spared. Opioid related death rates were relatively stable [2],
while the prevalence of opioids in driving under the influence cases was significantly lower
than in other provinces [21]. Furthermore, opioid related hospitalizations rate is still the
lowest in the country [6]. Even though the number of opioids prescription per capita
remains similar to other provinces, the quantity prescribed is lower, yielding the lowest
country-wide defined daily doses [6]. NSO have been detected in several cases (drug
seizures, driving under the influence of drugs and overdoses) in Canada since 2011 [20].
However, their appearance has mostly mirrored the development of the opioids epidemic.
In that sense, the three cases presented therein might be a harbinger of the crisis to come
in the province of Que´bec.
In addition to an increasing number of cases, the diversification of NSO can also bring
supplemental analytical challenges due to their structural similarity. The third case pre-
sented here is a good example of this problematic aspect. Two misidentification occurred
in the first analysis of the white powder: isobutyrylfentanyl, which was not initially in the
LC-MS/MS method scope, was mistaken for the targeted butyrylfentanyl (Figure 1) and
U-48800 was erroneously identified as U-51754 by GC-MS spectrum database comparison.
Analysis by an LC-MS/MS NSO screening method under development allowed discrimi-
nation of the compounds. This type of confusion is likely to be observed with many pairs
of NSO isomers, such as para-fluorobutyrylfentanyl and para-fluoroisobutyrylfentanyl,
or cyclopropylfentanyl and crotonylfentanyl. This can potentially lead to misidentifica-
tion of NSO, with serious issues in terms of interpretation and accuracy of published data.
The third case also emphasizes the importance of maintaining and updating GC-MS
spectra libraries to keep up with the pace of NSO apparition on the market. Initially,
GC-MS appears like a method of choice for screening illicit drugs in this constantly evolv-
ing market, due to the ability to compare results to worldwide shared spectra libraries.
However, GC-MS limits of detection for analysis targeting NSO are typically between
1 and 10 ng/mL [22]. A similar situation arises with high resolution mass spectrome-
ters (HRMS) (e.g., time of flight mass spectrometers (Q-TOF-MS)) which proved their
reliability in doing non-targeted and retrospective analysis. Despite that, like GC-MS,
HRMS instruments are known to be less sensitive than triple quadrupole systems in tar-
get mode analysis [23]. As numerous sources reported concentrations under 2 ng/mL
for both postmortem [23, 24, 25, 26] or antemortem [27, 28] cases, LC-MS/MS analyses
remain relevant to detect biological concentrations of most potent NSO like carfentanil.
Even when laboratories do have the technology and the capability to monitor NSO
in circulation, interpretation challenges still need to be addressed. Biological concen-
trations reported here are similar to those found in other publications. For example,
Mohr et al. reported on five polyintoxication cases positive for both furanylfentanyl
(2.5–76 ng/mL, mean 26 ng/mL) and U-47700 (17–490 ng/mL, mean 253 ng/mL) [29],
akin to what was found in cases 1 and 2 here. Martucci et al. also reported a case with
furanylfentanyl at concentrations of 1.9 ng/mL in peripheral blood and 2.8 ng/mL in
cardiac blood [30]. But the contribution of an NSO in an intoxication fatality is dif-
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ficult to assess and could not reliably be done here, mainly because only a handful of
studies containing post-mortem concentrations have been reported yet for human sub-
jects [3, 31, 32]. Therefore, suspected effects and concentrations have to be inferred from
animal studies. Nonetheless, these substances are reputed to easily cross the blood brain
barrier and interact with opioid receptors. Like traditionally prescribed opioids, they can
cause the classical opioid toxidrome including respiratory depression, miosis and altered
mental state [22, 31, 32, 33].
Beyond their individual psychoactive effects, the combined action of NSO between
themselves or with other drugs remains to elucidate. This is an important topic to con-
sider since NSO can be used as adulterant in counterfeit opioids [32]. Furthermore, the
mixture of several NSO is a common theme in the three cases presented here. In the third
case, an impressive number of 17 different NSO were detected. To the best knowledge of
the authors, this is the first case reported in literature involving as many different NSO.
Since the beginning of 2018, analysis of pieces of evidence and biological specimens in
our laboratory routinely reveal NSO combinations.
5. Conclusions
This paper presents the concentration values in postmortem cases (femoral blood, car-
diac blood and urine) for the NSO 4-ANPP, furanylfentanyl, U-47700, p-fluoro(iso)butyryl-
fentanyl, methoxyacetylfentanyl and cyclopropylfentanyl (Table 1), which will contribute
to build a comprehensive database for toxicological interpretation.
The unprecedented spread of NPS and NSO across the world brings several chal-
lenges to the forensic toxicology community. The increasing number of cases, potential
for misidentification and low biological concentrations require sensitive, specific, exten-
sive and high throughput LC-MS/MS methods. These reliable analyses will be crucial
in providing relevant toxicological results to help sort out forensic cases involving NSO.
Additionally, they can be used as an investigation tool to better understand the trends
of the recreational markets.
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